Scholar Rock Holding Corporation (SRRK)
Stock Price:
$17.60 USD
0.15 (0.86%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
525.78M |
| Revenue (ttm) |
22.42M |
| Net Income (ttm) |
-57.32M |
| Shares Out |
29.81M |
| EPS (ttm) |
-2.01 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$17.60 |
| Previous Close |
$17.45 |
| Change ($) |
0.15 |
| Change (%) |
0.86% |
| Day's Open |
17.70 |
| Day's Range |
17.16 - 17.80 |
| Day's Volume |
69,857 |
| 52-Week Range |
6.95 - 21.92 |
More Stats
| Market Cap |
525.78M |
| Enterprise Value |
367.67M |
| Earnings Date (est) |
Aug 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
29.81M |
| Float |
14.27M |
| EPS (basic) |
-2 |
| EPS (diluted) |
-2.01 |
| FCF / Share |
-1.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.87M |
| Short Ratio |
16.46 |
| Short % of Float |
11.89% |
| Beta |
0.84 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
23.46 |
| PB Ratio |
5.91 |
| Revenue |
22.42M |
| Operating Income |
-60.53M |
| Net Income |
-57.32M |
| Free Cash Flow |
-47.58M |
| Net Cash |
158.11M |
| Net Cash / Share |
5.29 |
| Gross Margin |
-150.45% |
| Operating Margin |
-270.04% |
| Profit Margin |
-255.70% |
| FCF Margin |
-212.28% |
| ROA |
-21.83% |
| ROE |
-58.43% |
| ROIC |
-61.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$28.25*
(60.51% upside)
Low
22.0
Current: 17.60
High
35.0
Target: 28.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 20.49 | - | - | 0.38 |
| Gross Profit | 20.49 | - | - | 0.38 |
| Operating Income | -54.54 | -50.69 | -25.03 | -16.21 |
| Net Income | -51.00 | -49.33 | -25.00 | -16.21 |
| Shares Outstanding | 27.54 | 15.66 | 1.63 | 1.60 |
| Earnings Per Share | -1.85 | -3.15 | -15.30 | -10.11 |
| Operating Cash Flow | -63.12 | 24.57 | -21.74 | -15.14 |
| Capital Expenditures | -3.11 | -1.49 | -0.36 | -0.79 |
| Free Cash Flow | -66.22 | 23.08 | -22.10 | -15.94 |
| Cash & Equivalents | 160 | 176 | 58.16 | 28.24 |
| Total Debt | 5.30 | 0.42 | 1.04 | 1.67 |
| Net Cash / Debt | 155 | 175 | 57.13 | 26.57 |
| Assets | 196 | 181 | 61.64 | 32.78 |
| Liabilities | 83.48 | 74.71 | 5.93 | 4.75 |
| Book Value | 113 | 107 | -53.52 | -30.03 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Scholar Rock Holding Corporation |
| Country |
United States |
| Employees |
93 |
| CEO |
Nagesh K. Mahanthappa |
Stock Information
| Ticker Symbol |
SRRK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SRRK |
| IPO Date |
May 24, 2018 |
Description
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, a novel inhibitor of the activation of myostatin, which is in Phase II clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.